ReviewCureus2026
Dual‑Energy CT in Inflammatory Arthritis: A Comprehensive Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory arthritis and crystal-associated arthropathies frequently present with overlapping clinical features, creating diagnostic and phenotypic challenges when conventional imaging findings are inconclusive. Dual-energy computed tomography (DECT) extends standard CT by enabling material-specific characterization, allowing differentiation of monosodium urate and calcium-containing deposits, and supporting selected applications beyond crystal detection. This narrative review synthesizes evidence from a curated set of PubMed-indexed studies to examine DECT principles, workflow considerations, interpretation pitfalls, and clinical utility across gout, calcium pyrophosphate deposition disease (CPPD), rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and osteoarthritis (OA). The focus is practical and clinically oriented, emphasizing qualitative evidence synthesis rather than quantitative pooling. DECT has its most established and evidence-supported role in gout, where it provides non-invasive crystal detection, burden mapping, and therapy monitoring. In CPPD, it functions primarily as a problem-solving adjunct when radiographs or ultrasound is inconclusive. In RA and PsA, applications such as iodine overlay imaging and virtual non-calcium reconstruction remain adjunctive and exploratory, with magnetic resonance imaging continuing as the reference standard for inflammatory assessment. In axSpA, DECT strengthens structural staging and may offer selective adjunct marrow evaluation, while in OA, its use is limited to targeted phenotyping in suspected crystal-overlap scenarios. Overall, DECT delivers the greatest clinical value when applied in a disease-specific, question-driven manner within multimodality imaging pathways and interpreted with attention to standardized protocols and potential artifacts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.